Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:43:42.463Z.
Calculation as of: 2026-10-06T16:43:42.463Z.
Quote observation: 2026-10-06T16:38:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0697fbf5b2c9a172e1581fe1039fb6f1f0c6a9f8a555274951ccff759adaa9ee
PE RATIO
N/A
Nexalin Technology, Inc.
Market Cap
$3.65M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Nexalin Technology, Inc. (NXL) | $3.65M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.40M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.55M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.46M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.35M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.24M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.89M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.18M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.98
Forward EPS (Est.)
$-11.42
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
